Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: President of Global R&D
Company: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
个人简介:
Dr. Lianshan Zhang holds the position of Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of dozens of NMEs across the globe. Prior to Hengrui, he was a senior research executive at Marcadia Biotech. From 1998 to 2008, Dr. Zhang was engaged in the discovery and development of peptide/protein therapeutics for the treatment of diabetes and obesity and successfully delivered multiple clinical candidates.  Dr. Lianshan Zhang obtained his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his Ph.D. in Organic Chemistry at the University of Tubingen. He conducted his post-doctoral research at University of Tubingen and Vanderbilt University.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Chairman and CEO
Company: Inmagene Biopharmaceuticals
个人简介:
Dr. Jonathan Wang has over 30 years of healthcare and life sciences experience, spanning entrepreneurship, investment, research, and finance. Under the supervision of Eric Kandel, a Nobel Laureate, he obtained a Ph.D. in Neurobiology from Columbia University where he was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship. He also earned an MBA from Stanford University.  Dr. Wang is the Chairman and CEO of Inmagene, a leading clinical-stage biotech company focused on immunology-related therapeutic areas.  With wholly owned subsidiaries in San Diego, Shanghai, Hangzhou and Wuhan, the company has raised approximately $140M financing and is building a strong pipeline with over 10 drug candidates. The lead drug candidate, IMG-020, is about to enter global phase 2 or 3 trials for 5 autoimmune indications.  Dr. Wang was a Partner at OrbiMed, the world’s largest healthcare-dedicated investment firm.  He co-founded OrbiMed Asia where he led the establishment and management of $1.1B PE/VE funds.  He was named one of the top 10 healthcare investors in China.  He incubated Apollomics and Bridge (acquired), and served as Chairman at Apollomics and Angelalign. He is a HKEX Biotech Advisory Panel member and a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders.  He has authored two philosophy of science books.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Executive President of Fosun Pharma
Company: Fosun Pharma
个人简介:
Dr. Aimin Hui is the Executive President of Fosun Pharma, President of Global R&D, and Chief Medical Officer. He is currently the Director of Shanghai Key Laboratory of Stem Cell Therapy and the Deputy Director of the Oncology Committee of China Pharmaceutical Association. He was the Vice President of Global Clinical R&D of Sanofi and the Vice Chairman of the Academic Committee of the 5th China Academic Oncology Conference. He has led the global development, registration and marketing of several small molecule and biologic anti-cancer drugs such as Izaxomib and Isatuximab. He has led the development and registration of several innovative drugs such as Ixazomib and Avatrombopag in China. He has published more than 80 papers in New England Journal of Medicine, Nature Medicine, Lancet, Cell Cancer, etc. Recently, he led the collaboration between Fosun and BioNTech on the development and registration of mRNA vaccines in Greater China (already marketed in Hong Kong and Macau).
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: President
Company: Shanghai Cell Therapy Group
个人简介:
钱其军,医学博士,研究员,博士研究生导师。国家杰出青年科学基金获得者。现任上海细胞治疗研究院院长,上海细胞治疗工程技术研究中心主任,上海吴孟超联合诺贝尔奖获得者医疗科技创新中心主任、上海细胞治疗集团总裁。上海市优秀学科带头人,上海市领军人才,上海市“五一劳动奖章”获得者,国家重点研发计划项目精准医疗专项首席科学家。现任中国医药质量管理协会细胞治疗质量控制与研究专业委员会等8个行业学会的副主任委员,9个行业学会常务委员、常务理事、委员及理事。先后主持承担国家科技重大专项、863项目、国自然杰青、海外杰青、重大项目、重点项目、面上项目等国家级课题16项。获国家科学技术进步创新团队奖1项,省部级二等奖4项,三等奖3项。共发表国内外论文380多篇,其中SCI论文83篇。